Patent: 9,522,876
✉ Email this page to a colleague
Summary for Patent: 9,522,876
Title: | Cytotoxic and anti-mitotic compounds, and methods of using the same |
Abstract: | Compounds having cytotoxic and/or anti-mitotic activity are disclosed. The compounds have the following structure (I): ##STR00001## including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having structure (I). |
Inventor(s): | Winters; Geoffrey C. (Vancouver, CA), Mandel; Alexander L. (Vancouver, CA), Hedberg; Bradley J. (Vancouver, CA), Babcook; John (Vancouver, CA), Rich; James R. (Vancouver, CA), Hsieh; Tom Han Hsiao (Vancouver, CA), Bourque; Elyse Marie Josee (Blaine, WA) |
Assignee: | ZYMEWORKS INC. (Vancouver, BC, unknown) |
Application Number: | 14/213,504 |
Patent Claims: | see list of patent claims |
Details for Patent 9,522,876
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2033-03-15 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2033-03-15 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2033-03-15 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |